Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Nanomedicine. 2020 Jun 12;29:102236. doi: 10.1016/j.nano.2020.102236

Figure 5: α-CD99-A192 has anti-leukemic activity in primary AML cells.

Figure 5:

A) A trypan blue viability assay was performed in MOLM-13, MV4-11 and U937 cells treated with α-CD99-A192 or an A192 control for 72 hours. The number of live cells was normalized to untreated cells. Data represented as mean ± SD, n=6. B-C) Alamar blue staining was performed in MOLM-13, MV4-11, and U937 cells to determine the IC50 of α-CD99-A192 at 48 hours post-treatment with the increasing concentration of α-CD99-A192 and plotted based on non-linear regression.